Kyverna Therapeutics has completed its rolling BLA submission to the FDA for mivocabtagene autoleucel (miv-cel), an investigational autologous CD19-directed CAR-T cell therapy for stiff person syndrome (SPS).
The company is requesting priority review under the therapy's RMAT designation.
If approved, miv-cel would become the first FDA-approved treatment for SPS and the first CAR-T cell therapy approved for an autoimmune disease.
The completed BLA is supported by results from the phase 2 KYSA-8 registrational trial, which evaluated miv-cel in patients with SPS. One-year follow-up data presented at MS Toronto in October demonstrated sustained clinical benefit across all primary and secondary endpoints, with patients maintaining improvements in disability measures following a single infusion. Nearly all patients also remained off chronic immunotherapies.
The therapy demonstrated a consistent safety profile, with no high-grade cases of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS), and no reported cases of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS).
Kyverna is advancing commercial preparations in anticipation of a potential 2027 U.S. launch, including engaging CAR-T treatment centers, neurologists and payers, and establishing patient support and reimbursement infrastructure.
Beyond SPS, Kyverna is evaluating miv-cel in generalized myasthenia gravis and progressive multiple sclerosis. Enrollment in the phase 3 KYSA-6 trial in gMG is expected to conclude in mid-2027. The FDA has also granted miv-cel RMAT designation for non-active secondary progressive multiple sclerosis.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!